CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — Aug 14, 2026
CERo Therapeutics Holdings filed Prospectus Supplement No. 15 on August 14, 2026, updating its December 2025 S-1 resale prospectus covering 729,596,950 shares of common stock with its Q2 2026 Form 10-Q. The attached 10-Q raises substantial doubt about the company's ability to continue as a going concern: CERo held just $937,512 of cash, restricted cash and equivalents at June 30, 2026 against a roughly $30.9 million working capital deficit, a $97.8 million accumulated deficit, and a $6,914,744 net loss for the first half of 2026 with no revenue.
Key figures
- Revenue
- 0
- Total Debt
- 4579500
- Debt Amount
- 4579500
- Total Assets
- 1899971
- Cash Position
- 937512
- Interest Rate
- 10
- Maturity Date
- April 9, April 27, May 28, July 9, and August 6, 2027 (various convertible note tranches)
- Shares Outstanding
- 71630992
- G and a 6m
- 4617837
- R and d 6m
- 4074357
- Option shares
- 45833762
- Warrant shares
- 159724
- Restricted cash
- 74756
- Total liabilities
- 32405268
- Accumulated deficit
- 97752859
- Deemed dividends 6m
- 28426624
- Srx max loan amount
- 1413600
- Reverse split ratios
- ["1-for-100 (Jan 8, 2025)","1-for-20 (Jun 13, 2025)"]
- Last bid price common
- 0.0095
- Nasdaq delisting date
- 2025-10-31
- Note conversion shares
- 700229358
- Last bid price warrants
- 0.0025
- Keystone eloc commitment
- 25000000
- Cash and equivalents only
- 862756
- Unamortized debt discount
- 3832853
- Preferred conversion shares
- 1033865400
- Shares registered for resale
- 729596950
- Anti dilutive potential shares
- 1780088244
- Convertible notes net carrying
- 746647
- Working capital deficit approx
- 30900000
- Net cash provided by financing 6m
- 4364091
- Preferred stock liabilities series d
- 8784862
- Preferred stock liabilities series e
- 6189020
- Preferred reclassified from equity q2
- 21584122
- Derivative liabilities convertible notes
- 7663855
AI analysis
Red flags9 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.